GERMANTOWN, Md., Feb. 28 /PRNewswire-FirstCall/ -- Advancis Pharmaceutical Corporation , a pharmaceutical company focused on developing and commercializing novel anti-infective products, today announced that it has rehired a former Advancis executive to lead the Company's sales and commercial product initiatives and also expanded its marketing team.
James Bruno rejoined Advancis on February 2, 2006, as vice president of sales, bringing more than 15 years of sales experience at leading pharmaceutical companies with an expertise in anti-infectives. Bruno will be focused on developing Advancis' sales and commercialization infrastructure for its existing Keflex antibiotic franchise. In addition, he will contribute to the preparation for the potential commercialization of the Company's new Keflex line extension products and its portfolio of proprietary PULSYS antibiotic products.
In addition, the Company announced that on February 27, 2006, it hired Seung Baick as assistant product director, responsible for planning and executing the Company's Keflex marketing initiatives. Baick brings considerable experience in the biotechnology and pharmaceutical industries with expertise in strategic marketing, market research, and commercial planning.
"I am pleased to welcome James back to Advancis and am glad to add Seung to our marketing team. As we continue to advance our Keflex and Amoxicillin PULSYS product candidates, their combined experience in launching products and building commercial capabilities will serve the Company very well," said Dr. Edward M. Rudnic, president and CEO. "We are very fortunate to be able to reacquire James and to bring Seung onboard, and we look forward to their contributions in further developing our commercial capabilities."
Bruno served as vice president, international marketing at MedImmune, where his responsibilities included coordinating the international launch of a monoclonal antibody and managing MedImmune's distribution partners. He also served as marketing director of infectious disease products at Pharmacia Corporation and SmithKline Beecham.
Baick was manager, business development and portfolio planning at Cellective Therapeutics. He also served as product manager at Human Genome Sciences where he supported the commercial development of its oncology and immunology products.
About Advancis Pharmaceutical:
Advancis Pharmaceutical Corporation is a pharmaceutical company focused on the development and commercialization of pulsatile drug products that fulfill substantial unmet medical needs in the treatment of infectious disease. The Company is developing a portfolio of anti-infective drugs based on its novel biological finding that bacteria exposed to antibiotics in frontloaded staccato bursts, or "pulses," are killed more efficiently and effectively than those under standard treatment regimens. Based on this finding, Advancis has developed a proprietary, once-a-day pulsatile delivery technology called PULSYS(TM). By examining the resistance patterns of bacteria and applying its delivery technologies, Advancis has the potential to redefine infectious disease therapy and significantly improve drug efficacy, shorten length of therapy, and reduce drug resistance versus currently available antibacterial products. For more on Advancis, please visit http://www.advancispharm.com.
About Keflex:
Keflex(R) (cephalexin capsules, USP) is a first-generation cephalosporin antibiotic shown to be active against strains of both gram-positive and gram- negative aerobes in vitro and in clinical infections. Keflex is indicated for treatment of the following infections: respiratory tract infections, otitis media, skin and skin structure infections, bone infections, and genitourinary tract infections. More information on Keflex and prescribing information are available at http://www.advancispharm.com/products/keflex.
This announcement contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements are based on Advancis' current expectations and assumptions. These statements are not guarantees of future performance and are subject to a number of risks and uncertainties that would cause actual results to differ materially from those anticipated. The words, "believe," "expect," "intend," "anticipate," and variations of such words, and similar expressions identify forward-looking statements, but their absence does not mean that the statement is not forward- looking. Statements in this announcement that are forward-looking include, but are not limited to, statements about the Company's future development plans, clinical trials, and financial results.
The actual results realized by Advancis could differ materially from these forward-looking statements, depending in particular upon the risks and uncertainties described in the Company's filings with the Securities and Exchange Commission. These include, without limitation, risks and uncertainties relating to the Company's financial results and the ability of the Company to (1) reach profitability, (2) prove that the preliminary findings for its product candidates are valid, (3) receive required regulatory approvals, (4) successfully conduct clinical trials in a timely manner, (5) establish its competitive position for its products, (6) develop and commercialize products that are superior to existing or newly developed competitor products, (7) develop products without any defects, (8) have sufficient capital resources to fund its operations, (9) protect its intellectual property rights and patents, (10) implement its sales and marketing strategy, (11) successfully attract and retain collaborative partners, (12) successfully develop, receive regulatory approval, and commercialize any new Keflex products, and (13) retain its senior management and other personnel. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of today's date. Advancis undertakes no obligation to update or revise the information in this announcement, whether as a result of new information, future events or circumstances or otherwise.
Advancis Pharmaceutical CorporationCONTACT: Bob Bannon of Advancis Pharmaceutical Corporation,+1-301-944-6710, or ir@advancispharm.com
Web site: http://www.advancispharm.com/
